Drugs / Enavogliflozin
Enavogliflozin
Trials 33 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT07213310 | Nov 2025 → Jan 2026 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT06644404 | Oct → Dec 2024 overdue | — | Daewoong Pharmaceutical Co. LTD. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05747664 | Apr 2023 → Apr 2024 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05797922 | Mar → May 2023 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05737771 | Jan → Mar 2023 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05500898 | Aug → Oct 2022 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05192395 | Apr → May 2022 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT05207176 | Feb → Apr 2022 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05321732 | Dec 2021 → Aug 2022 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04343547 | Apr → Jul 2020 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04221399 | Jan → Aug 2020 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04064073 | Aug → Nov 2019 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT03364985 | Dec 2017 → May 2019 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04014023 | Jul 2019 → Mar 2020 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07619833 | Jun 2026 → Nov 2027 expected | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06606093 | Sep 2024 → Sep 2026 expected | diabetic kidney disease | Daewoong Pharmaceutical Co. LTD. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06141980 | Dec 2023 → Sep 2025 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT06027307 | Oct 2023 → Jun 2027 expected | heart failure, tricuspid valve insufficiency | Asan Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05466643 | Mar 2023 → Sep 2024 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT05505994 | Sep 2022 → Feb 2024 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT05376930 | Sep 2021 → May 2022 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT05376969 | May 2021 → May 2022 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT04654390 | Dec 2020 → Dec 2021 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT04634500 | Nov 2020 → Nov 2021 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT04632862 | Nov 2020 → Nov 2021 | type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT07240844 | Jan 2026 → Apr 2027 expected | amyloidosis | Seoul St. Mary's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06528262 | Apr 2025 → May 2027 expected | atrial fibrillation | Yonsei University | Recruiting | No outcome recorded |
| Phase 4 | NCT06782139 | Jan → Dec 2025 overdue | type 2 diabetes mellitus | Korea University Anam Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05672836 | Dec 2024 → Dec 2028 expected | aortic valve stenosis, heart failure | Duk-Woo Park, MD | Recruiting | No outcome recorded |
| Phase 4 | NCT06580717 | Oct 2024 → Nov 2026 expected | hypertrophic cardiomyopathy | Yonsei University | Recruiting | No outcome recorded |
| Phase 4 | NCT06350487 | May 2024 → Dec 2025 | heart failure | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT06399835 | Feb 2024 → Dec 2026 expected | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06642623 | Jan 2024 → Sep 2029 expected | cardiovascular disorder, kidney disorder, type 2 diabetes mellitus | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 34 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enavogliflozin | “Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development.” PMID 36756676 ↗ Feb 202312“DWP16001 enavogliflozin (single oral dose) is administered in accordance with the study protocol.” NCT07213310 ↗ “Enavogliflozin (0.3mg oral tablet once daily) will be administrated.” NCT06350487 ↗ “The drug in this study is called enavogliflozin.” NCT06606093 ↗ “Enavogliflozin 0.3mg, once daily” NCT06644404 ↗ |
| Known as | DWP16001 | “DWP16001 0.3mg” NCT06606093 ↗ |
| Known as | Envlo tab | “SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab)” NCT06350487 ↗ |
| Known as | ODP-9401 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3703921 ↗ |
| Action | Inhibit | “sodium-glucose cotransporter-2 inhibitor” PMID 36756676 ↗ Feb 2023 |
| Modality | Small molecule | — CHEMBL3703921 ↗ |
| Route | Oral | “orally” NCT03364985 ↗ |